Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis &Amp; Other Neuromuscular Disorders
Conditions
Keywords
Amyotrophic Lateral Sclerosis, MSC, biomedicine
Brief summary
This retrospective observational study will analyze de-identified clinical data from patients with amyotrophic lateral sclerosis (ALS) collected at multiple centers over 7 years. The primary objective is to describe disease progression using the ALS Functional Rating Scale-Revised (ALSFRS-R). Secondary objectives include evaluating survival, ventilatory decline, and correlations between available biomarkers (e.g., neurofilament light chain, cytokines) and disease trajectory. No new interventions or patient contact will occur.
Interventions
BIOLOGICALImaging and Clinical Reports
Inclusion of existing imaging data (MRI, EMG reports) and standard clinical documentation, where available.
Sponsors
Biocells Medical
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of amyotrophic lateral sclerosis (ALS) or motor neuron disease confirmed. 2. Age ≥18 years. 3. Availability of at least one ALS Functional Rating Scale-Revised (ALSFRS-R) score. 4. Availability of longitudinal follow-up data.
Exclusion criteria
1. Patients with alternative diagnoses that mimic ALS (e.g., multifocal motor neuropathy, cervical myelopathy, myasthenia gravis). 2. Absence of medical records
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of decline in ALS Functional Rating Scale-Revised (ALSFRS-R) scores | 2 yearss after the first administration | Unit: points per month |
Countries
Poland
Outcome results
None listed